189 related articles for article (PubMed ID: 35296193)
1. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
4. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma.
Ahmed NM; Youns M; Soltan MK; Said AM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1110-1120. PubMed ID: 31117890
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Fan X; Deng J; Shi T; Wen H; Li J; Liang Z; Lei F; Liu D; Zhang H; Liang Y; Hao X; Wang Z
Bioorg Chem; 2021 Sep; 114():105154. PubMed ID: 34378540
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract][Full Text] [Related]
12. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.
Rezende Miranda R; Fu Y; Chen X; Perino J; Cao P; Carpten J; Chen Y; Zhang C
J Med Chem; 2020 Oct; 63(20):11484-11497. PubMed ID: 33030342
[TBL] [Abstract][Full Text] [Related]
13. Novel Pyridine Bioisostere of Cabozantinib as a Potent
Karmacharya U; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575841
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol-sorafenib hybrids.
Awasthi BP; Chaudhary P; Guragain D; Jee JG; Kim JA; Jeong BS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1884-1897. PubMed ID: 34340602
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer evaluation of 6-azacyclonol-2,4,6-trimethylpyridin-3-ol derivatives: M3 muscarinic acetylcholine receptor-mediated anticancer activity of a cyclohexyl derivative in androgen-refractory prostate cancer.
Karmacharya U; Chaudhary P; Lim D; Dahal S; Awasthi BP; Park HD; Kim JA; Jeong BS
Bioorg Chem; 2021 May; 110():104805. PubMed ID: 33725508
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads.
Zhang Q; Hu Z; Shen Q; Chen Y; Lu W
Molecules; 2017 May; 22(5):. PubMed ID: 28498316
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19.
Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S
Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.
Nie W; Lu Y; Pan C; Gao J; Luo M; Du J; Wang J; Luo P; Zhu H; Che J; He Q; Dong X
Bioorg Chem; 2022 Apr; 121():105673. PubMed ID: 35217375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
